Mankind Pharma Limited
Company's authorized capital stands at Rs 4100.0 lakhs and has 97.7045% paid-up capital which is Rs 4005.88 lakhs. Mankind Pharma Limited last annual general meet (AGM) happened on 23 Sep, 2017. The company last updated its financials on 31 Mar, 2017 as per Ministry of Corporate Affairs (MCA).
Mankind Pharma Limited is majorly in Business Services business from last 34 years and currently, company operations are active. Current board members & directors are SURENDRA LUNIA, RAMESH JUNEJA, RAJEEV JUNEJA, RAJEEV JUNEJA, PRABHA ARORA, PREM KUMAR ARORA, SHEETAL ARORA, ARJUN JUNEJA, PRADEEP CHUGH, ASHUTOSH KUMAR DHAWAN, SANDIP SHARMA, ANUJ GIROTRA, LEONARD LEE KIM and SATISH KUMAR SHARMA .
Company is registered in Delhi (Delhi) Registrar Office. Mankind Pharma Limited registered address is 208, Okhla Industrial Estate, Phase-III, New Delhi South Delhi DL 110020 IN.
Mankind Pharma Limited Details
| CIN | U74899DL1991PLC044843 |
| Date of Incorporation | 03 Jul, 1991 |
| Status | Active |
| Company Category | Company limited by Shares |
| Company Sub-category | Non-govt company |
| Company Class | Public |
| Business Activity | Business Services |
| Authorized Capital | 4100.0 lakhs |
| Paid-up Capital | 4005.88 lakhs |
| Paid-up Capital % | 97.7045 |
| Registrar Office City | Delhi |
| Registered State | Delhi |
| Registration Number | 44843 |
| Registration Date | 03 Jul, 1991 |
| Listing Status | Unlisted |
| AGM last held on | 23 Sep, 2017 |
| Balance Sheet Date | 31 Mar, 2017 |
Mankind Pharma Limited News
Generic versions of key diabetic drug in market double in a month
Post patent expiry, numerous Indian companies launched generic versions of Empagliflozin. The market witnessed a surge in brands and players in April. This makes diabetes drugs more affordable for Indian patients. Prices have dropped significantly, increasing access. Doctors are optimistic about the future. More patent expirations will further benefit patients. Semaglutide's upcoming patent expiry could revolutionize diabetes treatment.
Reckitt Benckiser's rare reflection: India a big growth driver
Reckitt Benckiser's CEO, Kris Licht, highlighted India as a key growth driver, anticipating sustained strong volume growth alongside China. The company's success is fueled by strong organic performance in germ protection (Dettol) and intimate wellness (Durex). Reckitt's strategic alignment with India's public health goals has deepened market penetration.
Tariff risks cloud near-term pharma deals outlook: Rothschild's Stefano Beschi
Uncertainty surrounding potential US tariffs is threatening to disrupt India's booming pharma deal market, according to Rothschild & Co. While short-term M&A activity may slow due to a lack of confidence and predictability, the industry remains resilient in the long run.
As Empagliflozin goes off patent, 71 copies of the key diabetes drug roll out in a month
Following the expiration of Empagliflozin's patent, the Indian pharmaceutical market has seen a surge, with 71 new brands and 17 companies introducing their versions. This influx has significantly increased sales, driven by prices that are 80-90% lower than the original. The increased affordability is expected to improve access for a wider population, with further market expansion anticipated.
SC seeks govt response on advancing emission standard deadline for NCR power plants
The Supreme Court has asked the Environment Ministry if the deadline for Delhi's 'Category C' power plants to comply with sulphur dioxide emission standards can be advanced from December 31, 2029. The bench led by Justice AS Oka aims to prevent repeated deadline extensions. Additionally, questions were raised regarding reclassification of thermal power plants within 300 km of Delhi.
*Ministry of Corporate Affairs, 2019, Company/LLP Data, (Government of India administrative body to govern and regulate corporate affairs through the Companies Act 1956 & 2013 including other allied Acts, Bills and Rules) http://www.mca.gov.in/, Updated as on 04 Dec, 2018.
Please Note: Data on this page may not be updated vis-à-vis company's current credentials.